Alkermes Share Holder Equity 2010-2024 | ALKS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Alkermes share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Alkermes share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.9B
Regeneron Pharmaceuticals (REGN)	$125.5B
Vertex Pharmaceuticals (VRTX)	$122.4B
Gilead Sciences (GILD)	$104.4B
Bristol Myers Squibb (BMY)	$100.8B
CSL (CSLLY)	$96.8B
GSK (GSK)	$87.9B
Alnylam Pharmaceuticals (ALNY)	$35.1B
Argenex SE (ARGX)	$31.6B
Biogen (BIIB)	$28.8B
BioNTech SE (BNTX)	$27.5B
Moderna (MRNA)	$26.9B
Illumina (ILMN)	$20.9B
BeiGene (BGNE)	$19.2B
Genmab (GMAB)	$17.3B
BioMarin Pharmaceutical (BMRN)	$13.5B
Vaxcyte (PCVX)	$13B
Exact Sciences (EXAS)	$12.8B
Incyte (INCY)	$12.6B
Insmed (INSM)	$12.5B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.4B
Bio-Rad Laboratories (BIO.B)	$9.1B
Legend Biotech (LEGN)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.7B
Repligen (RGEN)	$8B
Intra-Cellular Therapies (ITCI)	$7.9B
Halozyme Therapeutics (HALO)	$7.9B